Gilles Boire, M. D., M. Sc.

Investigator Gilles Boire
Inflammation-Pain Axis
Centre de recherche du CHUS

Rheumatologist
Centre hospitalier universitaire de Sherbrooke

Full professor
Department of Medicine | Division of Rheumatology
Faculty of Medicine and Health Sciences
Université de Sherbrooke

Contact Information
Phone | 819 346-1110 ext. 15063

E-Mail | Gilles.Boire@USherbrooke.ca

  

Research relevance

Developing predictive biomarkers of clinical outcomes in patients with recent-onset inflammatory polyarthritis. Developing efficient interprofessionnal collaboration for the secondary prevention of fragility fractures 

The investigator Gilles Boire' career started with some important observations in the Ro/anti-Ro antigenic system. Some of these experiments led to the identification of the anti-Sa/citrullinated vimentin antibody, a highly specific biomarker for rheumatoid arthritis. He thus initiated in 1997 a longitudinal observational cohort of patients with recent onset inflammatory polyarthritis. The patients are treated with the target of 0 swollen joint, using the best strategies available. At each predetermined visit, detailed demographic, clinical, radiological and psychosocial data are stored as well as samples of serum, genomic DNA and RNA extracted from peripheral blood, and in vitro osteoclastogenesis. The cohort is still recruiting and is now more than 650 strong, with a follow up of 5 years, making it ideal to test existing and new potential biomarkers, both locally and with collaborators from Canada and USA.

In parallel, due to the clinical observation of a severe therapeutic gap in the secondary prevention of bone fragility fractures, Dr Boire established a program to facilitate the collaboration between various health specialists (orthopaedic surgeons, medical specialists, family physicians, nurses, fall prevention programs). After establishing the efficacy of the program in the Sherbrooke area, he is now implementing and evaluating a similar program in 5 areas of the Province of Québec.

 

To top

Representative Achievements

  • IRSC. Early prediction of patient-related and radiological outcomes in patients with recent-onset inflammatory polyarthritis (EPA) using established and novel independent predictors.    March 2011- Feb 2016
  • IRSC - Partenariats pour l'amélioration des soins de santé. Partnership for applied research in fracture prevention programs in the elderly (March 2012 - Feb 2015)
  • Bouffard P, Barbar E, Brière F, Boire G.  "Interaction cloning and characterization of RoBP1, a novel protein binding to human Ro ribonucleoproteins".  RNA, 6:66-78, 2000
  • Carrier N, Cossette P, Daniel C, de Brum-Fernandes AJ, Liang P, Ménard HA and Boire G. The DERAA HLA-DR alleles in Patients with Early Polyarthritis: Protection Against Severe Disease and Lack of Association with RA Autoantibodies. Arthritis & Rheumatism 2009 Mar;60(3):698-707
  • Roux S, Beaulieu M, Beaulieu MC, Cabana F, Boire G. Priming Primary Care Physicians to Treat Osteoporosis After a Fragility Fracture: An Integrated Multidisciplinary Approach. Journal of Rheumatology 2013; 40:5;(In Press)  doi:10.3899/jrheum.120908

           

Know-How & Opportunities for Collaboration

  • Rheumatology
  • Longitudinal observational cohorts
  • Development of biomarkers
  • Autoantibodies
  • Ribonucleoproteins
  • Multidisciplinar collaboration

      

To top